| Raymond Hm Schaerf, MD | |
|
2601 W Alameda Ave, Ste 404, Burbank, CA 91505-4813 | |
| (818) 843-2334 | |
| (818) 843-1781 |
| Full Name | Raymond Hm Schaerf |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 52 Years |
| Location | 2601 W Alameda Ave, Burbank, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912903295 | NPI | - | NPPES |
| 00G390400 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 208G00000X (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cedars-sinai Medical Center | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cedars-sinai Medical Center Pharmacy 3 | 0446169114 | 648 |
News Archive
Biomedical engineering researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed inexpensive paper pumps that use capillary action to power portable microfluidic devices, opening the door to a range of biomedical tools.
The Department of Health and Human Services has mailed out a third round of $250 checks to help seniors who enter the Medicare Part D coverage pay gap for prescription drugs, WCAX [in Vermont] reports. "The one-time payment aims to close a gap in coverage for prescription medication. The rebates will go to about 9,000 Vermonters whose out-of-pocket expenses already total more than $940 for the year" (8/11).
A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese.
Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex on the webcast to discuss data from the study.
› Verified 4 days ago
| Entity Name | Cedars-sinai Medical Center Pharmacy #3 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639172372 PECOS PAC ID: 0446169114 Enrollment ID: O20040204000886 |
News Archive
Biomedical engineering researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed inexpensive paper pumps that use capillary action to power portable microfluidic devices, opening the door to a range of biomedical tools.
The Department of Health and Human Services has mailed out a third round of $250 checks to help seniors who enter the Medicare Part D coverage pay gap for prescription drugs, WCAX [in Vermont] reports. "The one-time payment aims to close a gap in coverage for prescription medication. The rebates will go to about 9,000 Vermonters whose out-of-pocket expenses already total more than $940 for the year" (8/11).
A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese.
Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex on the webcast to discuss data from the study.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raymond Hm Schaerf, MD 2601 W Alameda Ave, Ste 404, Burbank, CA 91505-4813 Ph: (818) 843-2334 | Raymond Hm Schaerf, MD 2601 W Alameda Ave, Ste 404, Burbank, CA 91505-4813 Ph: (818) 843-2334 |
News Archive
Biomedical engineering researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed inexpensive paper pumps that use capillary action to power portable microfluidic devices, opening the door to a range of biomedical tools.
The Department of Health and Human Services has mailed out a third round of $250 checks to help seniors who enter the Medicare Part D coverage pay gap for prescription drugs, WCAX [in Vermont] reports. "The one-time payment aims to close a gap in coverage for prescription medication. The rebates will go to about 9,000 Vermonters whose out-of-pocket expenses already total more than $940 for the year" (8/11).
A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese.
Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex on the webcast to discuss data from the study.
› Verified 4 days ago